Sapna R. Srivastava
Director/Board Member chez INNOVIVA, INC.
Fortune : 1 M $ au 30/06/2023
Profil
Sapna R.
Srivastava is an Independent Non-Executive Director at Aura Biosciences, Inc., an Independent Director at SQZ Biotechnologies Co., an Independent Director at Innoviva, Inc., a Director at AsclepiX.
Therapeutics LLC, an Independent Director at Nuvalent, Inc., a Director at Alumis, Inc., an Independent Director at Tourmaline Bio, Inc., and a Strategic Advisor at BioPlus Acquisition Corp.
She previously served as an Independent Director at MYOS RENS Technology, Inc. from 2014 to 2016, an Independent Director at Talaris Therapeutics, Inc., a Director at VelosBio, Inc. in 2020, an Independent Director at Social Capital Suvretta Holdings Corp.
II from 2021 to 2023, an Independent Director at Talaris Therapeutics, Inc. from 2021 to 2023, the Chief Financial & Strategy Officer at Abide Therapeutics, Inc. from 2017 to 2019, a Research Analyst at Morgan Stanley & Co. LLC, an Analyst at Goldman Sachs & Co. LLC in 2010, an Analyst at Thomas Weisel Partners LLC in 2010, the Chief Financial & Strategy Officer at Intellia Therapeutics, Inc. from 2015 to 2016, and the Chief Financial Officer at eGenesis, Inc. in 2021.
She also worked as an Associate at Jp Morgan Direct Corporate Finance.
Dr. Srivastava holds a doctorate degree from New York University School of Medicine and an undergraduate degree from St. Xavier's College (Mumbai).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INNOVIVA, INC.
0,05% | 22/05/2023 | 30 173 ( 0,05% ) | 459 837 $ | 31/03/2024 |
| 30/03/2023 | 30 000 ( 0,47% ) | 310 500 $ | 30/06/2023 | |
| 30/03/2023 | 30 000 ( 0,12% ) | 310 500 $ | 30/06/2023 | |
0,00% | 23/10/2023 | 518 ( 0,00% ) | 11 862 $ | 31/03/2024 |
NUVALENT, INC. CLASS A
-.--% | 15/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
AURA BIOSCIENCES INC
-.--% | 07/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
| 31/12/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Sapna R. Srivastava
| Sociétés | Poste | Début |
|---|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Director/Board Member | 23/10/2020 |
| AURA BIOSCIENCES, INC. | Director/Board Member | 01/05/2021 |
| NUVALENT, INC. | Director/Board Member | 01/07/2021 |
| BIOPLUS ACQUISITION CORP. | Corporate Officer/Principal | - |
| INNOVIVA, INC. | Director/Board Member | 01/01/2023 |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | Director/Board Member | 02/08/2022 |
AsclepiX Therapeutics LLC
 AsclepiX Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services AsclepiX Therapeutics LLC engages in biologics and drug development technology. It specializes in anti-angiogenesis therapy, ophthalmology, oncology, and immunology. The company was founded by Jordan J. Green and Aleksander S. Popel and is headquartered in Baltimore, MD. | Director/Board Member | 01/12/2019 |
Anciens postes connus de Sapna R. Srivastava
| Sociétés | Poste | Fin |
|---|---|---|
| TOURMALINE BIO, INC. | Director/Board Member | 26/10/2023 |
| SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. II | Director/Board Member | 31/07/2023 |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Sapna R. Srivastava
| St. Xavier's College (Mumbai) | Undergraduate Degree |
| New York University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| AURA BIOSCIENCES, INC. | Health Technology |
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| INNOVIVA, INC. | Health Technology |
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| NUVALENT, INC. | Health Technology |
| SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. II | Finance |
| Entreprise privées | 12 |
|---|---|
MYOS RENS Technology, Inc.
 MYOS RENS Technology, Inc. Medical SpecialtiesHealth Technology MYOS RENS Technology, Inc. operates as a nutrition company, develops and markets products that improve muscle health and performance. Its primary product is Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk, intended to increase lean muscle mass, size, and strength. The company was founded on April 11, 2007 and is headquartered in Cedar Knolls, NJ. | Health Technology |
Abide Therapeutics, Inc.
 Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Health Technology |
Morgan Stanley & Co. LLC
 Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | Finance |
Goldman Sachs & Co. LLC
 Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Finance |
Thomas Weisel Partners LLC
 Thomas Weisel Partners LLC Investment Banks/BrokersFinance Founded in 1998, Thomas Weisel Partners (TWP) is a broker/dealer headquartered in San Francisco with offices in New York City, Boston, Denver, Colorado and Palo Alto, California. The firm is a subsidiary of Thomas Weisel Partners Group, Inc. (Nasdaq: TWPG), a San Francisco-based investment banking firm. Their ultimate parent is Stifel Financial Corp. (NYSE: SF). TWP's investment banking, brokerage and equity research divisions serve emerging growth companies and institutional investors around the world. They are a member of the NYSE, the SIPC and FINRA. TWP specializes in the growth sectors of the economy with a particular focus on the consumer, energy, healthcare, Internet, media/telecommunications, metals/mining and technology sectors. Within the consumer sector, the firm focuses on: financial products, gaming/lodging, interactive market services, lifestyles/sports retailers, restaurants and hardlines and softlines retailing. TWP's global energy research is provided by analysts in three countries and covers the following trends: (1) fast-growing oil and natural gas producers in North America and worldwide (2) domestic and international energy service companies and (3) alternative energy technology and resource developers. Within the healthcare sector, TWP focuses on: biotechnology, diagnostics, healthcare information technology, pharmaceutical services, life science technology, medical devices and specialty pharmaceuticals. The firm's interest in the Internet, media and telecommunications sector include: Internet services, media, broadcasting and telecommunications services. Their focus within the metals and mining sector include: base metals, gold, precious metals and uranium. TWP's technology research focuses on: (1) applied technologies (2) communications components (3) core and wireless communications equipment (4) IP networking communications equipment (5) electronic supply chain (6) enterprise hardware (7) information and financial technology services (8) semiconductor capital equipment (9) broadline and specialty semiconductors (10) applications and communications software and (11) infrastructure software. TWP also provides value-added equities analysis across a variety of sectors including: industrials, financials, consumer, technology and healthcare. | Finance |
Talaris Therapeutics, Inc.
 Talaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company, which engages in the development of allogeneic hematopoietic stem cell transplantation. The company was founded by Suzanne Ildstad on February 15, 2002 and is headquartered in Wellesley, MA. | Health Technology |
eGenesis, Inc.
 eGenesis, Inc. Miscellaneous Commercial ServicesCommercial Services eGenesis, Inc. operates research platform to deliver human transplantable cells, tissues, and organs grown in pigs. It uses gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation. The company was founded by George M. Church, Yang Luhan, Prashant Mali, Geoff Mackay and Guell Marc in 2015 and is headquartered in Cambridge, MA. | Commercial Services |
AsclepiX Therapeutics LLC
AsclepiX Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services AsclepiX Therapeutics LLC engages in biologics and drug development technology. It specializes in anti-angiogenesis therapy, ophthalmology, oncology, and immunology. The company was founded by Jordan J. Green and Aleksander S. Popel and is headquartered in Baltimore, MD. | Commercial Services |
VelosBio, Inc.
 VelosBio, Inc. Miscellaneous Commercial ServicesCommercial Services VelosBio, Inc. operates as an biopharmaceutical company. It developes antibody-drug conjugates to treat hematological cancers and solid tumors. The company was founded in 2017 and is headquartered in San Diego, CA. | Commercial Services |
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | Health Technology |
BioPlus Acquisition Corp.
 BioPlus Acquisition Corp. Financial ConglomeratesFinance BioPlus Acquisition Corp. is an early stage blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It focuses on identifying an opportunity in the life sciences industry. The company was founded on February 11, 2021 and is headquartered in New York, NY. | Finance |
| Jp Morgan Direct Corporate Finance |
